Agency Forms Undergoing Paperwork Reduction Act Review, 41790 [2012-17292]
Download as PDF
41790
Federal Register / Vol. 77, No. 136 / Monday, July 16, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC).
Centers for Disease Control and
Prevention
Background and Brief Description
The ART program reporting system is
used to comply with Section 2(a) of
Public Law 102–493 (known as the
Fertility Clinic Success Rate and
Certification Act of 1992 (FCSRCA)), 42
U.S.C. 263a–1(a)). FCSRCA requires
each ART program to annually report to
the Secretary through the CDC
pregnancy success rates achieved by
each ART program, the identity of each
embryo laboratory used by such ART
program, and whether the laboratory is
certified or has applied for certification
under the Act. The reporting system
allows CDC to publish an annual
success rate report to Congress as
specified by the FCSRCA.
CDC requests OMB approval to
continue information collection for
three years. This Revision request
includes an increase in the total
estimated burden hours due to an
increase in the estimated number of
responding clinics and an increase in
the estimated number of responses per
respondent. In addition, this Revision
request describes implementation of a
brief, one-time optional feedback survey
at the end of the data submission for
[30 Day–12–0556]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Assisted Reproductive Technology
(ART) Program Reporting System (0920–
0556, exp. 9/30/2012)—Revision—
National Center for Chronic Disease and
Public Health Promotion (NCDDPHP),
each reporting year. The feedback
survey will elicit information about
ART reporting system usability as well
as respondents’ perspectives on the
usefulness of the information collection.
Information is collected electronically
through the National ART Surveillance
System (NASS), a web-based interface,
or by electronic submission of NASScompatible files. The NASS includes
information about all ART cycles
initiated by any of the ART programs
practicing in the United States and its
territories. The system also collects
information about the pregnancy
outcome of each cycle as well as a
number of data items deemed important
to explain variability in success rates
across ART programs and individuals.
Respondents are the 484 ART
programs in the United States.
Approximately 440 ART programs are
expected to report an average of 339
ART cycles each. The burden estimate
includes the time for collecting,
validating, and reporting the requested
information. Information is collected on
an annual schedule.
There are no costs to the respondents
other than their time. The total
estimated annualized burden hours are
96,960.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Form name
ART Programs ................................................
NASS ..............................................................
Feedback Survey ...........................................
Kimberly S. Lane,
Deputy Director, Office of Science Integrity,
Office of the Associate Director for Science,
Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2012–17292 Filed 7–13–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
srobinson on DSK4SPTVN1PROD with NOTICES
[Docket No. FDA–2012–N–0001]
Advisory Committee for
Pharmaceutical Science and Clinical
Pharmacology; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
VerDate Mar<15>2010
16:32 Jul 13, 2012
Jkt 226001
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Advisory
Committee for Pharmaceutical Science
and Clinical Pharmacology.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on August 9, 2012, from 8 a.m. to
5 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
440
176
Number of
responses per
respondent
339
1
Average
burden per
response (in
hours)
39/60
2/60
to the White Oak Campus must enter
through Building 1.
Contact Person: Yvette Waples, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533, email:
ACPS-CP@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), to find out
further information regarding FDA
advisory committee information. A
notice in the Federal Register about last
minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site at
https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
E:\FR\FM\16JYN1.SGM
16JYN1
Agencies
[Federal Register Volume 77, Number 136 (Monday, July 16, 2012)]
[Notices]
[Page 41790]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17292]
[[Page 41790]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-12-0556]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-7570 or send an email to
omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-5806.
Written comments should be received within 30 days of this notice.
Proposed Project
Assisted Reproductive Technology (ART) Program Reporting System
(0920-0556, exp. 9/30/2012)--Revision--National Center for Chronic
Disease and Public Health Promotion (NCDDPHP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The ART program reporting system is used to comply with Section
2(a) of Public Law 102-493 (known as the Fertility Clinic Success Rate
and Certification Act of 1992 (FCSRCA)), 42 U.S.C. 263a-1(a)). FCSRCA
requires each ART program to annually report to the Secretary through
the CDC pregnancy success rates achieved by each ART program, the
identity of each embryo laboratory used by such ART program, and
whether the laboratory is certified or has applied for certification
under the Act. The reporting system allows CDC to publish an annual
success rate report to Congress as specified by the FCSRCA.
CDC requests OMB approval to continue information collection for
three years. This Revision request includes an increase in the total
estimated burden hours due to an increase in the estimated number of
responding clinics and an increase in the estimated number of responses
per respondent. In addition, this Revision request describes
implementation of a brief, one-time optional feedback survey at the end
of the data submission for each reporting year. The feedback survey
will elicit information about ART reporting system usability as well as
respondents' perspectives on the usefulness of the information
collection.
Information is collected electronically through the National ART
Surveillance System (NASS), a web-based interface, or by electronic
submission of NASS-compatible files. The NASS includes information
about all ART cycles initiated by any of the ART programs practicing in
the United States and its territories. The system also collects
information about the pregnancy outcome of each cycle as well as a
number of data items deemed important to explain variability in success
rates across ART programs and individuals.
Respondents are the 484 ART programs in the United States.
Approximately 440 ART programs are expected to report an average of 339
ART cycles each. The burden estimate includes the time for collecting,
validating, and reporting the requested information. Information is
collected on an annual schedule.
There are no costs to the respondents other than their time. The
total estimated annualized burden hours are 96,960.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
ART Programs.......................... NASS.................... 440 339 39/60
Feedback Survey......... 176 1 2/60
----------------------------------------------------------------------------------------------------------------
Kimberly S. Lane,
Deputy Director, Office of Science Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2012-17292 Filed 7-13-12; 8:45 am]
BILLING CODE 4163-18-P